Results 171 to 180 of about 3,894,411 (305)

The ubiquitin-proteasome system in Alzheimer's disease: mechanism of action and current status of treatment. [PDF]

Front Aging Neurosci
Jia S, Li Q, Rui X, Qin W, Zhang W, Dou J, Zhang X.   +6 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science. [PDF]

Clin Transl Sci
Walley AH, Dupuis LN, Woodahl EL, Killam SR.   +3 more
europepmc   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab. [PDF]

Blood Neoplasia
Lorenzo-Mohamed M, Vicario-Bueno C, Díaz-Tejedor A, González-Rodríguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, González-Méndez L, Martín-Sánchez M, Garayoa M, Paíno T.   +10 more
europepmc   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Mechanisms and Recent Advances of Small-Molecule Therapeutics in Rosacea Treatment

Clinical, Cosmetic and Investigational Dermatology
Maogen Ye,1,2 Pingsheng Hao,1 Nana Luo,1 Tianhao Li1 1Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610000, People’s Republic of China; 2Chengdu University of Traditional Chinese Medicine, Chengdu ...
Ye M, Hao P, Luo N, Li T
doaj  

The mechanism of action of digoxin requires the sodium-dependent inactivation of the sodium-calcium exchanger. [PDF]

Sci Adv
Scranton K, John S, Angelini M, Zhang R, Schwingshackl A, Goldhaber JI, Olcese R, Ottolia M.   +7 more
europepmc   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source